Inhibition of SUV39H1 in different types of cancer also stimulates interferon signaling, enhances cancer cell immunogenicity, reduces the expression of inhibitory receptors, and generally improves the efficacy of T-cell therapy [11,32,90]. This evidence concerns the gene SUV39H1 and cancer.